Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome
- Conditions
- Thrombotic MicroangiopathiesAtypical Hemolytic Uremic Syndrome
- Interventions
- Biological: OMS721
- Registration Number
- NCT03205995
- Lead Sponsor
- Omeros Corporation
- Brief Summary
The purpose of this study is to evaluate the platelet count change from baseline and safety of OMS721 in adults and adolescents with atypical hemolytic uremic syndrome (aHUS). The study will also evaluate pharmacokinetics (PK), pharmacodynamics (PD), and anti-drug antibody response (ADA).
- Detailed Description
This is a Phase 3, multicenter study of OMS721 in adults and adolescents with atypical hemolytic uremic syndrome (aHUS). The uncontrolled, open-label study will evaluate the effect of OMS721 in subjects with plasma therapy-resistant aHUS and plasma therapy-responsive aHUS. This study has four periods: Screening, Treatment Induction, Treatment Maintenance, and Follow-up. Approximate enrollment is 80 subjects. An interim analysis will be performed after 40 subjects have completed 26 weeks of treatment for potential registration.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 80
- Competent to provide informed consent, or if a minor, have at least one parent or legal guardian to provide informed consent with written assent from the subject.
- Are at least 12 years old at screening (Visit 1).
- Have a clinically diagnosis of primary atypical hemolytic uremic syndrome (aHUS), with ADAMTS13 activity greater than 5% in plasma.
- Plasma therapy-resistant aHUS patients must have a screening platelet count less than 150,000/uL, evidence of microangiopathic hemolysis, and serum creatinine greater than upper limit of normal.
- Plasma therapy-responsive aHUS patients must have documented history of requiring plasma therapy to prevent aHUS exacerbation and received plasma therapy at least once every 2 weeks at an unchanged frequency for at least 8 weeks before first dose of OMS721.
- Have STEC-HUS, a direct positive Coombs test, history of hematopoietic stem cell transplant, and/or HUS from an identified drug.
- History of vitamin B12 deficiency-related HUS, systemic lupus erythematosus, and/or antiphospholipid syndrome.
- Active cancer or history of cancer (except non-melanoma skin cancers) within 5 years of screening.
- Have been on hemodialysis or peritoneal dialysis for greater than or equal to 12 weeks.
- Have an active systemic bacterial or fungal infection requiring systemic antimicrobial therapy (prophylactic antimicrobial therapy administered as standard of care is allowed).
- Baseline resting heart rate less than 45 beats per minute or greater than 115 beats per minute.
- Baseline QTcF greater than 470 milliseconds.
- Have malignant hypertension (diastolic blood pressure [BP] greater than 120 mm Hg with bilateral hemorrhages or "cotton-wool" exudates on funduscopic examination).
- Have a poor prognosis with a life expectancy of less than three months in the opinion of the Investigator.
- Are pregnant or lactating.
- Have received treatment with an investigational drug or device within four weeks prior to screening.
- Have abnormal liver function tests defined as ALT or AST > five times ULN.
- Have HIV infection.
- History of cirrhosis of the liver.
- Have previously completed treatment in an OMS721study.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description OMS721 OMS721 Administration of OMS721
- Primary Outcome Measures
Name Time Method The effect of OMS721 as measured by platelet count change from baseline 26 weeks The effect of OMS721 will be evaluated in subjects with aHUS by changes in platelet count from baseline
- Secondary Outcome Measures
Name Time Method Incidence of antidrug antibodies (ADA) 771 days post-dose Incidences of ADA in subjects with aHUS, administered OMS721
Increase in eGFR 26 weeks Increase of greater than 15 ml/min/1.73 m2 in eGFR calculated by the MDRD Equation
TMA Remission 26 weeks Platelet count greater than or equal to 150,000/μL over at least 2 consecutive weeks, within the initial 26-week period
Change from baseline in serum creatinine 26 weeks Assessment of subject's change from baseline in serum creatinine
Safety as measured by incidences of Adverse Events, vital signs, ECG, and clinical laboratory tests Pre-dose and up to 771 days post-dose Assessment of safety of OMS721 in subjects with aHUS by incidence of Adverse Events, clinically significant vital sign abnormalities, ECG abnormalities, and clinical laboratory test abnormalities
Hematological Normalization 26 weeks Normalization of platelet count and normalization of serum LDH by 2 consecutive measurements over at least 4 consecutive weeks, within the initial 26-week period
Change from baseline in serum LDH 26 weeks Assessment of subject's change from baseline in serum LDH
TMA Response 26 weeks Complete TMA response defined as normalization of platelet count, normalization of serum LDH, and \> 25% decrease in serum creatinine by at least 2 consecutive measures over at least 4 consecutive weeks, within the initial 26-week period
TMA event-free status 26 weeks No decrease in platelet count of \> 25% from baseline, no plasma exchange or plasma infusion, and no initiation of new dialysis over at least 12 consecutive weeks, within the initial 26-week period
Change from baseline in haptoglobin 26 weeks Assessment of subject's change from baseline in haptoglobin
Pharmacokinetics (PK): Trough plasma concentration, lower limit of quantification (LLOQ) Days 1-4; Treatment Maintenance (103 weeks): 17 visits; Rescue Therapy (if occurs): RT Days 1-4; Follow-Up at Day 771 Pharmacokinetics (PK): Area under time-concentration curve (AUC) Days 1-4; Treatment Maintenance (103 weeks): 17 visits; Rescue Therapy (if occurs): RT Days 1-4; Follow-Up at Day 771 Pharmacodynamics (PD): Inhibition of C4 activity Days 1-4; Treatment Maintenance (103 weeks): 17 visits; Rescue Therapy (if occurs): RT Days 1-4; Follow-Up at Day 771 Pharmacokinetics (PK): Maximum plasma concentrations (Cmax) Days 1-4; Treatment Maintenance (103 weeks): 17 visits; Rescue Therapy (if occurs): RT Days 1-4; Follow-Up at Day 771 Pharmacodynamics (PD): Inhibition of C3 activity Days 1-4; Treatment Maintenance (103 weeks): 17 visits; Rescue Therapy (if occurs): RT Days 1-4; Follow-Up at Day 771
Trial Locations
- Locations (1)
Omeros Investigational Site
🇺🇸Chicago, Illinois, United States